- A dedicated session will highlight new advancements
in hemodiafiltration therapy showcasing its potential to
improve patient outcomes through enhanced toxin removal in dialysis
treatments.
- Company-wide researchers and clinical experts share insights
from large global databases, revealing crucial trends in kidney
failure etiology, cardiovascular risks, and treatment modalities
across different regions.
- Nearly 75 abstracts presented across a broad range of
cutting-edge research, covering topics from the global impact of
dialysis to advancements in kidney care technology, sustainability,
and health equity.
BAD HOMBURG, Germany, Oct. 21,
2024 /PRNewswire/ -- Fresenius Medical Care (FME),
the world's leading provider of products and services for
individuals with renal diseases, today announced the presentation
of nearly 75 company-affiliated research abstracts at the American
Society of Nephrology's (ASN) Kidney Week 2024 taking place
October 24-27 in San Diego.
"We are pleased to present research that exemplifies our ongoing
commitment to advancing kidney care on a global scale," said
Frank Maddux, MD, Global Chief
Medical Officer at Fresenius Medical Care. "This
year's abstracts highlight key innovations in treatment
approaches, including high-volume hemodiafiltration, as well as the
integration of artificial intelligence. We aim to leverage insights
from Fresenius Medical Care's global databases to improve patient
outcomes and drive more equitable, sustainable care for people
working to live meaningful lives with kidney
disease worldwide."
Fresenius Medical Care has provided an educational grant to the
American Society of Nephrology in support of an educational
symposium during Kidney Week, The Role of Hemodiafiltration in
the Management of Dialysis-Dependent Chronic Kidney Failure, on
October 25, 2024, 12:45 PM PDT - 01:45 PM PDT.
In recent years, hemodiafiltration (HDF) has been increasingly
recognized for the treatment of patients with kidney failure
requiring dialysis. HDF uses enhanced convection in combination
with diffusion to improve the removal of large solutes such as
beta-2-microglobulin and kappa and lambda light chains. While HDF
has been used in Europe widely for
many years, beginning in 2025, Fresenius Medical Care will
gradually introduce this therapy into its Fresenius Kidney Care
dialysis clinics in the United
States. In February 2024, Fresenius Medical Care
received FDA 510(k) clearance for the company's 5008X Hemodialysis
System, an HDF and HighVolumeHDF-capable dialysis machine in
the U.S.
At the ASN Kidney Week 2024, scientific and medical experts from
across Fresenius Medical Care will present research related to many
important topics in kidney disease care. Highlights of this
year's presentations include:
Advancing High-Volume Hemodiafiltration (HVHDF)
- Mortality Risk on Hemodiafiltration Compared with
High-Flux Hemodialysis: Real-World Evidence from a Large Brazilian
Cohort: Patients undergoing online hemodiafiltration (HDF) have
been associated with better survival compared to those on high-flux
hemodialysis (HD). Recently, the use of HDF has grown markedly in
Brazil, but there is no robust
real-world Brazilian study on the impact of this dialysis modality
on patient's outcomes.
- Hemodiafiltration Is Associated with Lower Hospitalization
Rates Compared with Hemodialysis in a Singapore Cohort:
Hemodialysis (HD) patients suffer from high rates of
hospitalization leading to significant morbidity, mortality, and
costs. Hemodiafiltration (HDF) has been shown to improve patient
outcomes.
- Adequate Convective Volume Can Be Achieved in Majority of
Multiethnic Asian Patients Receiving Hemodiafiltration in
Singapore: High-volume
hemodiafiltration (HDF) has been shown to improve patient outcomes.
However, there is a very common concern amongst healthcare
practitioners about the feasibility of achieving optimal convective
volume (CV) in Asian patients.
Sustainability and Equity in Kidney Care
- High Prevalence and Inequities in Unmet Social Risk in Diverse
Urban Patients on Hemodialysis: Health-related social risks
(SR) are associated with adverse health outcomes amongst patients
with kidney disease. We aimed to identify and analyze SR in a
diverse population of hemodialysis (HD) patients.
- Survival Sex Differences among Pediatric and Young
Adult Hemodialysis Patients in the Global MONDO Registry: For
all age groups, women with ESKD on HD have higher rates of
cardiovascular (CV) events compared to men, but their all-cause
mortality is reduced. Survival in pediatric and young adult HD
patients (pts) from across the globe is understudied.
- Canadian Wildfires of 2023 and Risk of Mortality and
Hospitalization Among ESKD Patients: Climate change driven
droughts are increasing frequency and intensity of wildfires, a
significant source of air pollution. Smoke plumes from the 2023
Canadian wildfires travelled long distances and negatively impacted
air quality across large swaths of eastern US. We investigated the
association between exposure to 2023 Canadian wildfire-related air
pollutants and risk of mortality and hospitalization among
hemodialysis patients in New England, the Mid-Atlantic, and the
Midwest U.S.
Harnessing the Power of Global Databases to Drive
Care
- Cardiovascular Morbidity Patterns in Patients on Dialysis
Globally in Apollo Dial DB: Cardiovascular diseases (CVDs) affect
most people with kidney failure but are undefined globally. We
aimed to analyze CVD prevalence among dialysis patients treated in
40 countries across six continents, as represented in the first
version of a global dialysis database called Apollo Dial DB.
- Profiles of Home Medication Use in Patients on Dialysis
Globally: Global patterns of medication use in dialysis are
undefined. This project aims to provide a real-world view of home
medication use in dialysis using a global dialysis dataset from 40
countries. The most common prescribed medications administered at
home by patients were compared by modality.
- Changes in Fluid Overload during the First 6 Months of Dialysis
among More than 13,000 Patients: Fluid overload (FO) is a
recognized risk factor for mortality in dialysis patients; however,
less has been reported on factors related to changes in FO.
Whole-body bioimpedance spectroscopy (BIS) has been validated for
hydration assessment. We used Body Composition Monitor (BCM) data,
a whole-body BIS, to evaluate changes in the degree of FO during
the first 6 months of hemodialysis (HD) or hemodiafiltration (HDF)
and characteristics associated with those changes using Apollo Dial
DB.
Leveraging Artificial Intelligence (AI), Computational
Medicine, and Advanced Analytics for Patient Care
- Arteriovenous Fistula Failure Prediction Using Single Treatment
Information: Predicting the natural course of AVF complications
with technical surveillance has been an elusive task. We developed
a machine learning algorithm assessing the risk of failure of AVF
using information collected by the dialysis machine in a single
treatment.
- Validation of a Cloud-Based Convolutional Neural Network
Classifying Arteriovenous Access Aneurysms in a Multicenter Study:
Arteriovenous (AV) access aneurysms may become life-threatening,
e.g., in the event of ruptures. We developed an artificial
intelligence classification application (ACA) that categorizes
aneurysms using AV access images. This study prospectively
evaluates ACA's classification of AV aneurysms against physicians
specializing in access care.
- Joint Modeling of Longitudinal Ferritin Trajectories and
COVID-19 Infections in Native American, Hispanic, and White
Patients on Hemodialysis: American Indians/Alaska Natives (AIAN)
and Hispanic individuals in the U.S. are overrepresented in the
hemodialysis (HD) population and were hardest hit by COVID-19.
Early in the pandemic, hyperferritinemia was linked to COVID-19
infections. Joint modeling learns from both longitudinal and
time-to-event data for predictive accuracy and dynamic estimation.
We investigated the predictive utility of ferritin w/ COVID-19
infection in a cohort of AIAN, Hispanic and White HD patients.
For more information about Fresenius Medical Care's presence at
ASN Kidney Week 2024, please visit
https://www.freseniusmedicalcare.com/en/ASN-2024/.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.1 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,757 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approx. 311,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care
does not undertake any responsibility to update the forward-looking
statements in this release.
Media contact
Kirsten
Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-showcases-research-and-innovations-in-kidney-care-at-american-society-of-nephrology-asn-kidney-week-2024-302281930.html
SOURCE Fresenius Medical Care Holdings, Inc.